The antileukemic activity of the alkylating compound PTT-119 has been evaluated on granulocyte-macrophage progenitors from 10 patients affected by chronic myelogenous leukemia (CML) in the chronic phase, either by adding the drug to the directly culture medium at concentrations varying from 0.10 μg/ml to 5 μg/ml or by incubating the cells for 30-min or 120-min with 1 to 20 μg/ml of the drug. Complete growth inhibition was never achieved after 30-min and 120-min treatments (48.5% ± 12.1 SD and 82.8% ± 9.7 SD at the higher drug concentration, respectively). In addition, chromosomal analysis on the same samples showed that the Ph1+ clone was still present. In contrast, continuous exposure to PTT-119 produced a complete inhibition of CML CFU-GM (97.2% ± 6.3 SD) at lower concentrations (5 μg/ml) suggesting the possible usefulness of testing PTT-119 effects at even lower concentrations in combination with other chemotherapeutic compounds or biological modifiers for therapeutic use.
|Number of pages||3|
|Journal||Cancer Journal (United States)|
|Publication status||Published - 1989|
ASJC Scopus subject areas
- Cancer Research